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Blockade of Atrial
Angiotensin II Type 1 Receptors
A Novel Antiarrhythmic
Strategy to Prevent Atrial Fibrillation?*
Helmut U. Klein, MD, Andreas Goette, MD
Magdeburg, Germany
Atrial fibrillation (AF) is known to cause significant changes
in atrial tissue architecture and atrial electrophysiology (1).
In recent years, it has become clear that preexisting alter-
ations (autonomic dysbalance, degenerative tissue changes,
fibrosis, and so forth) can provide an electrophysiologic and
morphologic substrate, which increases the likelihood of AF
onset in response to triggering events. Alterations of the
interstitial matrix in atrial tissue seem to be especially
significant contributing factors (1,2). Increased amounts of
fibrous tissue in fibrillating human atria were described 30
years ago (3). However, only recently potential molecular
mechanisms responsible for collagen accumulation in atrial
myocardium have been elucidated (4,5).
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One of the mediators responsible for the development of
atrial fibrosis is angiotensin II. Recent studies have shown
an increased atrial expression of the angiotensin-converting
enzyme (ACE) and activation of the angiotensin II–related
intracellular signal transduction pathway in fibrillating hu-
man tissue (4). In dogs, activation of the atrial angiotensin
II system has been described in a tachycardia-induced heart
failure (HF) model (5). It could be demonstrated that
inhibition of the ACE can reduce the generation of angio-
tensin II in this HF setting, which is also characterized by
less atrial fibrosis and a decreased inducibility of AF. The
molecular effects of ACE inhibitors may also explain the
reduced incidence of AF found in patients with left ven-
tricular dysfunction after myocardial infarction (6).
The study presented by Kumagai et al. (7) in this issue of
the Journal is the first to describe the impact of the
angiotensin II type 1 receptor blocker candesartan on
electrical and structural remodeling in canine atria. Using a
rapid atrial pacing model, the authors demonstrate that
blockade of the angiotensin II type 1 receptor reduces the
development of atrial fibrosis in dogs undergoing four weeks
of rapid atrial pacing, when compared with untreated
controls. In addition, candesartan shortened the duration of
induced episodes of AF. Angiotensin II receptor blockers
seem to have advantageous effects in this atrial pacing model
that are comparable with the described effects of ACE
inhibitors. Candesartan might offer a significant antiar-
rhythmic potential by reducing the amount of fibrous tissue
formation in the atria, avoiding heterogeneity and delay of
atrial activation. Thus, the results of the present study are of
potential clinical importance.
However, from the study by Kumagai et al. (7) it remains
unclear to what extent ventricular dysfunction might have
contributed to the development of atrial fibrosis in their
rapid atrial pacing model, because the ventricular rate was
not controlled by atrioventricular (AV) node ablation. The
development of tachycardia-induced ventricular myopathy
in this model may help to explain that four weeks of rapid
atrial pacing was accompanied by the development of atrial
fibrosis, resembling morphologic findings by Li et al. (2,5)
in an HF model. In contrast, atrial fibrosis has not been
observed in previous studies during rapid atrial pacing, in
which rapid AV-conduction was prevented by AV node
ablation (1,2). In patients with permanent AF, angiotensin
II type 1 receptors are down-regulated, whereas the amount
of the “antifibrotic” angiotensin II type 2 receptors are
up-regulated. This may limit the therapeutic effect of
angiotensin II type 1 receptor blockers in patients with
long-lasting episodes of AF (8). It might be possible,
however, that the down-regulation of “profibrotic” angio-
tensin II receptors is preceded by a period during which type
1 receptors are temporarily up-regulated. Unfortunately, the
time course of changes in angiotensin II receptor expression
has not been analyzed in the study by Kumagai et al. (7).
Despite its methodological limitations, this study supports
the significance of angiotensin II–dependent signal trans-
duction for interstitial accumulation of collagen in the atria
during AF. In contrast to most animal models, activation of
the atrial angiotensin II system and development of inter-
stitial fibrosis have been described in atrial myocardium in
patients without HF but with concomitant cardiovascular
disease—mainly systemic hypertension and valve disease
(1,9). Animal models of AF with at least some extent of
ventricular structural abnormalities represent the morpho-
logic atrial changes (e.g., fibrosis) found in the majority of
patients with AF. In contrast, atrial fibrosis is absent in AF
models with complete normal ventricular function (1),
which suggests that activation of the atrial angiotensin II
system is of minor importance during lone AF. The
observed “antiarrhythmic actions” induced by inhibition of
the angiotensin II–related effects seem to be related to their
influence on the interstitial matrix. A significant impact of
ACE inhibitors and angiotensin II receptor blockers on
atrial action potentials and on electrical remodeling has not
been demonstrated in the long-term (10).
Our insight into the specific interaction between the
interstitial matrix and electrophysiological properties in
atrial tissue is far from complete. Increased amounts of
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collagen and cellular hyperplasia of fibroblasts cause sepa-
ration of atrial myocytes—which slows atrial conduction—
and induce regional conduction block, which is the ideal
condition for the onset and perpetuation of AF (1,2,9).
However, the total amount of collagen per mm3 can be only
a rough estimate for related alterations of impulse conduc-
tion, because the orientation of collagen fibers with respect
to the alignment of myocytes may affect the conduction to
a far greater extent than just the overall amount of measured
fibrous tissue (11). Furthermore, disturbed cell-matrix in-
teraction by membrane-bound proteases can increase cell
mobility and weakens the mechanical resistance of the
myocardial architecture. This results in cell slippage, dila-
tion of the atria, and consecutive mechanical dysfunction of
the atrium (9). Thus, changes in the interstitial matrix are
linked to electrophysiological, mechanical, and morphologic
alterations (9). Whether all these interstitial changes are
related to the angiotensin II system is unclear. Further
studies are mandatory to prove which changes can be
produced by AF itself.
At the molecular level, several AF-related alterations of
atrial tissue are due to activation of different signal trans-
duction systems. For example, increased endothelin levels,
reduced amounts of bradykinin, and altered levels of tissue
proteases or cytokines can contribute to degenerative
changes of atrial myocardium, collagen accumulation, cel-
lular hypertrophy, and cell death (1,9). These mechanisms
may act synergistically to affect the spread of electrical
activation and beget AF. In addition to fibrotic changes,
deposits of other extracellular proteins or fibrils can also
contribute to conduction inhomogeneity. A recent study
(12) indicates that atrial amyloid depositions can be found
in patients with AF, mainly in patients with valve disease.
Interestingly, the amount of atrial amyloid is inversely
related to the amount of fibrous tissue, suggesting that, at
least in this selected group of patients, a therapeutic ap-
proach applying “antifibrotic” strategies may be ineffective.
Further studies are needed to define the role of different
molecular pathways and their dynamic interactions on
alterations of atrial electrophysiology. Better knowledge
about these fundamental mechanisms can help to identify
novel targets for pharmacologic interventions, which may be
even more effective than conventional antiarrhythmic ther-
apy. In this perspective, the presented study by Kumagai et
al. (7) provides interesting experimental evidence that can-
desartan reduces the accumulation of atrial collagen forma-
tion during AF. Their data help to explain the finding of the
study by Madrid et al. (13), who reported a beneficial effect
of irbesartan after electrical cardioversion.
Besides the growing body of experimental evidence dem-
onstrating the impact of angiotensin II on atrial myocar-
dium, prospective clinical trials are needed to confirm the
therapeutic effect of ACE inhibitors/angiotensin II type 1
receptor blockers in patients with AF. We have to define
clinical parameters that help to anticipate the presence of an
activated atrial angiotensin II system. Furthermore, we have
to determine the optimal therapeutic dose of ACE inhibi-
tors/angiotensin II type 1 receptor blockers as well as the
necessary duration of therapy for the treatment of patients
with “fibrosis-related” AF.
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